Availability for Non-Exclusive, Exclusive, or Partially Exclusive Licensing of U.S. Provisional Patent Application Concerning Monoclonal Antibodies Against Glycoprotein of Ebola Sudan Boniface Virus, 50960 [E9-23769]
Download as PDF
50960
pwalker on DSK8KYBLC1PROD with NOTICES
ACTION:
Federal Register / Vol. 74, No. 190 / Friday, October 2, 2009 / Notices
Notice of open meeting.
DEPARTMENT OF DEFENSE
SUMMARY: In accordance with Section
10(a) (2) of the Federal Advisory
Committee Act (Pub. L. 92–463),
announcement is made of the following
committee meeting:
Name of Committee: Department of
the Army Historical Advisory
Committee.
Date: October 22, 2009.
Time: 9 a.m. to 4:30 p.m.
Place: U.S. Army Center of Military
History, Collins Hall, Building 35, 103
Third Avenue, Fort McNair, DC 20319–
5058.
Proposed Agenda: Review and
discussion of the status of historical
activities in the United States Army.
FOR FURTHER INFORMATION CONTACT: Dr.
Richard Stewart, U.S. Army Center of
Military History, ATTN: AAMH–ZC,
103 Third Avenue, Fort McNair, DC
20319–5058; telephone number (202)
685–2709.
SUPPLEMENTARY INFORMATION: The
committee will review the Army’s
historical activities for FY 2009 and
those projected for FY 2010 based upon
reports and manuscript received
throughout the period. And the
committee will formulate
recommendations through the Chief of
Military History to the Chief of Staff,
Army, and the Secretary of the Army for
advancing the use of history in the U.S.
Army.
The meeting of the advisory
committee is open to the public.
Because of the restricted meeting space,
however, attendance may be limited to
those persons who have notified the
Advisory Committee Management
Office in writing at least five days prior
to the meeting of their intention to
attend the October 22, 2009, meeting.
Notifications should be addressed to the
Executive Secretary of the committee,
Dr. William Stivers, at the U.S. Army
Center of Military History, 103 Third
Avenue, Fort Lesley J. McNair, DC
20319–5058.
Any member of the public may file a
written statement with the committee
before, during, or after the meeting.
Such statements may be sent to the
Executive Secretary of the committee at
the address shown in the paragraph
above. To the extent that time permits,
the committee chairman may allow
public presentations or oral statements
at the meeting.
Dated: September 21, 2009.
Richard W. Stewart,
Chief Historian, Center of Military History.
[FR Doc. E9–23771 Filed 10–1–09; 8:45 am]
BILLING CODE 3710–08–P
VerDate Nov<24>2008
16:40 Oct 01, 2009
Jkt 220001
Department of the Army
Availability for Non-Exclusive,
Exclusive, or Partially Exclusive
Licensing of U.S. Provisional Patent
Application Concerning Novel Use and
Method of Rapamycin To Treat Toxic
Shock
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
SUMMARY: Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
231,348 entitled ‘‘Novel Use and
Method of Rapamycin to Treat Toxic
Shock,’’ filed August 5, 2009. The
United States Government, as
represented by the Secretary of the
Army, has rights to this invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Materiel
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Assessment,
(301) 619–6664, both at telefax (301)
619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates to the use of
Rapamycin as a treatment of toxic shock
induced by staphylococcal exotoxins;
more specifically, staphylococcal
enterotoxins that are potent activators
for human T cells and can cause lethal
shock.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9–23770 Filed 10–1–09; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive,
Exclusive, or Partially Exclusive
Licensing of U.S. Provisional Patent
Application Concerning Monoclonal
Antibodies Against Glycoprotein of
Ebola Sudan Boniface Virus
Department of the Army, DoD.
Notice.
AGENCY:
ACTION:
SUMMARY: Announcement is made of the
availability for licensing of the
invention set forth in U.S. Provisional
Patent Application Serial No. 61/
PO 00000
Frm 00015
Fmt 4703
Sfmt 4703
239,266 entitled ‘‘Monoclonal
Antibodies Against Glycoprotein of
Ebola Sudan Boniface Virus,’’ filed
September 2, 2009. The United States
Government, as represented by the
Secretary of the Army, has rights to this
invention.
ADDRESSES: Commander, U.S. Army
Medical Research and Material
Command, ATTN: Command Judge
Advocate, MCMR–JA, 504 Scott Street,
Fort Detrick, Frederick, MD 21702–
5012.
FOR FURTHER INFORMATION CONTACT: For
patent issues, Ms. Elizabeth Arwine,
Patent Attorney, (301) 619–7808. For
licensing issues, Dr. Paul Mele, Office of
Research and Technology Assessment,
(301) 619–6664, both at telefax (301)
619–5034.
SUPPLEMENTARY INFORMATION: The
invention relates generally to the field of
antibodies. More specifically the
invention relates to monoclonal
antibodies against glycoproteins of the
Ebola Sudan Boniface virus and
methods of producing and using the
same.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9–23769 Filed 10–1–09; 8:45 am]
BILLING CODE 3710–08–P
DEPARTMENT OF EDUCATION
Submission for OMB Review;
Comment Request
Department of Education.
The Director, Information
Collection Clearance Division,
Regulatory Information Management
Services, Office of Management invites
comments on the submission for OMB
review as required by the Paperwork
Reduction Act of 1995.
DATES: Interested persons are invited to
submit comments on or before
November 2, 2009.
ADDRESSES: Written comments should
be addressed to the Office of
Information and Regulatory Affairs,
Attention: Education Desk Officer,
Office of Management and Budget, 725
17th Street, NW., Room 10222, New
Executive Office Building, Washington,
DC 20503, be faxed to (202) 395–5806 or
send e-mail to
oira_submission@omb.eop.gov.
AGENCY:
SUMMARY:
Section
3506 of the Paperwork Reduction Act of
1995 (44 U.S.C. Chapter 35) requires
that the Office of Management and
Budget (OMB) provide interested
Federal agencies and the public an early
SUPPLEMENTARY INFORMATION:
E:\FR\FM\02OCN1.SGM
02OCN1
Agencies
[Federal Register Volume 74, Number 190 (Friday, October 2, 2009)]
[Notices]
[Page 50960]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-23769]
-----------------------------------------------------------------------
DEPARTMENT OF DEFENSE
Department of the Army
Availability for Non-Exclusive, Exclusive, or Partially Exclusive
Licensing of U.S. Provisional Patent Application Concerning Monoclonal
Antibodies Against Glycoprotein of Ebola Sudan Boniface Virus
AGENCY: Department of the Army, DoD.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: Announcement is made of the availability for licensing of the
invention set forth in U.S. Provisional Patent Application Serial No.
61/239,266 entitled ``Monoclonal Antibodies Against Glycoprotein of
Ebola Sudan Boniface Virus,'' filed September 2, 2009. The United
States Government, as represented by the Secretary of the Army, has
rights to this invention.
ADDRESSES: Commander, U.S. Army Medical Research and Material Command,
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick,
Frederick, MD 21702-5012.
FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul
Mele, Office of Research and Technology Assessment, (301) 619-6664,
both at telefax (301) 619-5034.
SUPPLEMENTARY INFORMATION: The invention relates generally to the field
of antibodies. More specifically the invention relates to monoclonal
antibodies against glycoproteins of the Ebola Sudan Boniface virus and
methods of producing and using the same.
Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. E9-23769 Filed 10-1-09; 8:45 am]
BILLING CODE 3710-08-P